CClinicalTrials.gg
CompletedNCT04339972Updated Aug 19, 2021Results posted

Low Intensity Focused Ultrasound Pulses (LIFUP) to Modulate Pain

An interventional study of LIFUP and Sham LIFUP in Healthy Adults, sponsored by Medical University of South Carolina. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-19.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Feb 2019, registered Apr 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The anterior nuclei of the thalamus in addition to periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) are integral regions of a supraspinal opioidergic structure that regulate pain perception. With the capability to influence deep neurological tissues, low intensity frequency ultrasound pulsation (LIFUP) can likely modulate this circuit and induce analgesia. LIFUP deep brain modulation is achieved by induction of focused mechanical waveforms that traverse the cranium and underlying brain tissue. The low frequency of the ultrasonic wave consequently alters neuronal transmission and causes action potential variations through mechanical means, rather than thermal.

The purpose of this study is to examine whether stimulation of the anterior nuclei of the thalamus via LIFUP induces analgesia. We hypothesize that suppression of the anterior nuclei of the thalamus will induce a temporary increase in pain tolerance. Moreover, the behavioral changes in pain will correlate with specific regional BOLD changes during pain.

Read the detailed description

LIFUP uses a single large concave, or multiple ultrasound transducers in a cap placed on the scalp to produce high frequency (100Hz) sonications for 30 seconds at a time for 10 trains of pulses. Unlike traditional diagnostic ultrasound, which constantly transmits ultrasound and 'listens' to the echo to form an image, LIFUP delivers the ultrasound in packets or pulses. For reasons that are not clear, pulsed ultrasound causes neurons to depolarize and fire. Bones typically block ultrasound waves. Cleverly, however, one can deliver the ultrasound from multiple sources and use the skull as a lens, to actually shape and focus the convergent beam deeper in the brain.

The clinical use of LIFUP thus uses MRI scans taken before stimulation to position and calculate how multiple ultrasonic pulsations will converge at a location in the brain (taking into account the bone dispersion of the beam from the skull). Since a small transducer like in diagnostic ultrasound cannot individually cause neuronal discharge, with LIFUP neuronal firing can be focused both deep (2-12cm under the cap; for comparison, traditional TMS can stimulate 1-3.4cm2 deep(9, 10)) and focally (as small as 0.5mm in diameter, and up to 1000mm; the facility of a standard, commercially-available 70mm figure-of-8 TMS coil is roughly 50mm2; (9, 10)). Interestingly, the pulse width of the carrying frequency of LIFUP (0.5ms) is strikingly similar to that used in all other pulsed neuromodulation therapies (DBS: 0.6ms, ECT: 0.5ms; TMS: 0.2ms; VNS: 0.5ms), suggesting that this timeframe is mechanistically meaningful. This is a good example of the common background science of brain stimulation that transcends the individual methods.

Researchers have examined the effects of LIFUP in preclinical and clinical settings, confirming its ability to safely stimulate neural tissue(11-14), proposing cellular mechanisms for its efficacy(13-19), and now using LIFUP in human patients(20). Monti et al. (2016) described a case study in which they used LIFUP to stimulate a comatose patient's thalamus.(20). Two pre-LIFUP assessments rated the patient as being in minimally conscious state (MCS). After sonication, the patient recovered motor and oromotor functions the next day, advancing to full language comprehension and communication by nodding and shaking his head. Five days post-LIFUP, the patient attempted to walk. While this study was neither blinded nor sham-controlled, the first application of therapeutic LIFUP in a human patient was encouraging and we expect more therapeutic applications of LIFUP and potential clinical trials in the future. If LIFUP continues to show clinical potential, it has the potential to supplant the role of DBS without the need for surgery. The key barrier to LIFUP replacing DBS for clinical applications is that by and large, DBS is used in a manner where the device is inserted and turned constantly on without attempting to fundamentally change circuit dynamics or behavior so that you could remove the device. Obviously, patients cannot permanently wear a LIFUP helmet. However, to the degree that we learn how to stimulate in ways that permanently change circuit behavior (LTD or LTP) without ablation, we may be able to substitute several sessions of LIFUP that can train and rewire the brain instead of permanently implanting hardware. LIFUP can certainly stimulate deep and focal and noninvasively and thus may be a key next step in the field of brain stimulation.

Information on the intervention to be studied. We will be using the Brainsonix Low intensity focused ultrasound pulsation device. (BX Pulsar 1001). Please see the manufacturers description (Technical Summary) along with appendixes about the actual safety of the device itself.

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Medical University of South Carolina is the lead sponsor of 852 studies on the registry; 165 are open to participants now.

Of its 128 completed or terminated interventional studies of FDA-regulated products, 101 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18-45 years of age
  • Healthy volunteer

Exclusion criteria

Exclusion Criteria:

  • seizure history (individual or family)
  • history of depression
  • hospitalizations or surgeries in the previous 6 months
  • currently experiencing pain
  • history of chronic pain
  • metal implants or objects (e.g. pacemakers, metal plates, wires)
  • pregnant
  • alcohol dependence
  • illicit drug use in the previous 6 months
  • known allergy to capsaicin
  • history of brain surgery or brain lesions
  • history of loss of consciousness (greater than 15 min)
  • on stimulants or medications that lower seizure threshold.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Active LIFUP then Sham LIFUP

    Real LIFUP is delivered to the participant for visit 1, followed by sham lifup visit 2

    Device: LIFUP

  • Sham comparator
    Sham LIFUP then Active LIFUP

    Sham LIFUP is delivered to the participant for visit 1, followed by real lifup visit 2

    Device: Sham LIFUP

Interventions

  • DeviceLIFUP

    Low Intensity Focused Ultrasound Pulsation (LIFUP) is an interesting new form of brain stimulation that may be possible to stimulate non-invasively, safely, deep in the brain with focal precision.

  • DeviceSham LIFUP

    The same as LIFUP but the device is not turned on and the subject does not receive any ultrasound.

06

What researchers measure

Primary outcomes

  1. Quantitative Sensory Threshold Temperature Levels (Degrees Celsius)

    Quantitative Sensory Testing (QST) is a valuable method for diagnosing peripheral nervous system disorders, including pain. This outcome quantifies the level of thermal stimulus temperature (degrees celsius) required for a participant to feel pain on their wrist. The temperatures will be recorded before and after LIFUP.

    Time frame: Change from Baseline 45 minutes after LIFUP in the scanner

  2. Number of Participants With Significant Functional MRI Blood Oxygen Level Dependent (BOLD) Signal Changes

    Blood oxygenation level dependent (BOLD) imaging is the standard technique used to generate images in functional MRI (fMRI) studies, and relies on regional differences in cerebral blood flow to delineate regional activity. We will measure the brain's BOLD signal as a response to thermal stimulus within the MRI scanner and determine whether a significant (p ≤ 0.005 uncorrected) increase or decrease in BOLD signal intensity is indicated as a result of either Active or Sham LIFUP.

    Time frame: Changes within 3 seconds after receiving LIFUP

07

Results

Posted Aug 19, 2021

Participant flow

Participant flow — Overall Study
MilestoneActive LIFUP Followed by Sham LIFUPSham LIFUP Followed by Active LIFUP
Started1514
Completed109
Not completed55
Withdrew: Scheduling issues33
Withdrew: Dropout11
Withdrew: Technical issues10
Withdrew: Claustraphobia01

Outcome measures

PrimaryQuantitative Sensory Threshold Temperature Levels (Degrees Celsius)

Quantitative Sensory Testing (QST) is a valuable method for diagnosing peripheral nervous system disorders, including pain. This outcome quantifies the level of thermal stimulus temperature (degrees celsius) required for a participant to feel pain on their wrist. The temperatures will be recorded before and after LIFUP.

Time frame:
Change from Baseline 45 minutes after LIFUP in the scanner
Reported as:
Mean · Degrees Celsius
Quantitative Sensory Threshold Temperature Levels (Degrees Celsius)
Degrees CelsiusActive LIFUPSham LIFUP
Quantitative Sensory Threshold Temperature Levels (Degrees Celsius).51 ± .31.08 ± .28
PrimaryNumber of Participants With Significant Functional MRI Blood Oxygen Level Dependent (BOLD) Signal Changes

Blood oxygenation level dependent (BOLD) imaging is the standard technique used to generate images in functional MRI (fMRI) studies, and relies on regional differences in cerebral blood flow to delineate regional activity. We will measure the brain's BOLD signal as a response to thermal stimulus within the MRI scanner and determine whether a significant (p ≤ 0.005 uncorrected) increase or decrease in BOLD signal intensity is indicated as a result of either Active or Sham LIFUP.

Time frame:
Changes within 3 seconds after receiving LIFUP
Reported as:
Number · Participants w/ significant BOLD changes
Number of Participants With Significant Functional MRI Blood Oxygen Level Dependent (BOLD) Signal Changes
Participants w/ significant BOLD changesActive LIFUPSham LIFUP
Number of Participants With Significant Functional MRI Blood Oxygen Level Dependent (BOLD) Signal Changes00

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active LIFUP0/19 (0%)0/19 (0%)0/19 (0%)
Sham LIFUP0/19 (0%)0/19 (0%)0/19 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Active LIFUP Followed by Sham LIFUPSham LIFUP Followed by Active LIFUPTotal
<=18 years000
Between 18 and 65 years10919
>=65 years000
Age, Continuous
Age, Continuous(years)Active LIFUP Followed by Sham LIFUPSham LIFUP Followed by Active LIFUPTotal
Mean24.5 ± 4.624.5 ± 4.624.5 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)Active LIFUP Followed by Sham LIFUPSham LIFUP Followed by Active LIFUPTotal
Female6511
Male448
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active LIFUP Followed by Sham LIFUPSham LIFUP Followed by Active LIFUPTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported10919
Region of Enrollment
Region of Enrollment(Participants)Active LIFUP Followed by Sham LIFUPSham LIFUP Followed by Active LIFUPTotal
United States10919
08

Study locations

1 site
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Sep 12, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided — yes. After the initial data analysis is complete and the primary papers are submitted, we will release anonymized data to other credible researchers who ask.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04339972
Lead sponsor
Medical University of South Carolina
Responsible party
Sponsor
First posted
Apr 9, 2020
Start date
Feb 1, 2019
Primary completion
Jul 1, 2020
Completion
Jul 1, 2021
Results posted
Aug 19, 2021
Last update
Aug 19, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion